Results
The ANODE trial reported a statistically significant reduction in
infection rates with the co-amoxiclav intervention, this was found to
yield an improvement of 0.017 QALYs over the placebo1.
The cost to the NHS of the intervention was also lower at £120 over 6
weeks compared to the placebo’s £194. This gives an ICER of
-£4403.14/QALY. Sensitivity analysis confirmed that the intervention was
dominant.